About this trial
The entirely subcutaneous implantable defibrillator (S-ICD) (Emblem, Boston Scientific, Marlborough, MA, USA) was introduced as a new therapeutic alternative to the conventional transvenous ICD in 2009 and implantations are rapidly expanding since then.1 Implantation of the S-ICD seems to reduce implant-related perioperative complications such as pneumothorax, hematoma and cardiac tamponade.
The aim of this multicenter registry is thus to assess the outcome of patients following an S-ICD implantation in a real-world setting.
Eligibility criteria
Qualifiers
Implantation of an S-ICD, regardless of the technique
At least 1 month of follow up
At least 1 post-implantation assessment, in accordance to the routine clinical practice of every center (e.g. in person visit or remote follow up)
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
University of Luebeck
Lead sponsor
Prof. Jürgen Kuschyk, M.D
Collaborator
Giovanni Forleo, M.D.
Collaborator
Mauro Biffi, M.D.
Collaborator